|
NICE issues second draft guidance on Pixuvri for treatment of aggressive non …
pharmabiz.com The European Medicines Agency’s (the EMA) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled phase 3 clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who have … |
|
You Shouldn’t Ignore Gilead’s Idelalisib
Motley Fool In early September, Gilead filed a new drug application with the Food and Drug Administration for idelalisib as a treatment for iNHL patients who fail to respond to treatment from current go-to drug rituximab — marketed as Rituxan by Biogen Idec … |
|
Thyroid Meeting Spotlights Dx, Tx of Cancer
MedPage Today “Although this result is disappointing, it is a very important finding since there is so much need for an effective therapy, and rituximab has been associated with so much hope,” Koenig said. A different small-molecule drug, however, has shown some … |
|
Special News: Gilead Sciences, Inc.(NASDAQ:GILD), Alcoa Inc (NYSE:AA)
SBWire (press release) It demonstrated “highly statistically significant efficacy” in patients receiving the treatment receiving idelalisib plus rituximab compared with those receiving rituximab alone, the company said. Are investors worried about the recent updates with … |
New therapeutic target for B-cell lymphomaDoctor TipsterStandard chemotherapy, called R-CHOP, consists of a combination therapy that includes a monoclonal antibody, a steroid and three other drugs ( rituximab , cyclophosphamide, doxorubicin, vincristin…
|
Volume Alert: Gilead Sciences, Inc. (NASDAQ:GILD), NPS Pharmaceuticals, Inc …
Market News Call It demonstrated “highly statistically significant efficacy” in patients receiving the treatment receiving idelalisib plus rituximab compared with those receiving rituximab alone, the company said. Is GILD A Strong At The GALE? Get Advantage Of Our Free … |
Trial Updates and Public Offering – Research Report on Gilead, Celgene, Ariad …PR Newswire (press release)Gilead reported that the safety profile of idelalisib was acceptable and consistent with prior experience in combination with rituximab in previ…
Indian rheumatologists view standalone centres of care to ensure easy access …pharmabiz.comA slew of newer disease-modifying biologics like etanercept (Enbrel), adalimumab (Humira), infliximab (Remicade), rituximab (Rituxan) and abatacept (Orencia) a…
ProHealth |
ME/CFS Patients Demand FDA Bring Pharma and Clinical Experts to the Table
ProHealth Rituximab is also showing promise in trials of ME/CFS patients. “The researchers and clinical experts involved in these studies are some of the top ME/CFS experts in the world and have the experience to know what outcome measures are best for ME/CFS … |
MedscapePositive Early-Phase Results for Ofatumumab in MSMedscapeOn September 25, the FDA added a boxed warning about the risk for reactivation of hepatitis B virus infection in patients who once had the virus to the product labeling for 2 drugs used f…